m-Amino-phenylimino-imidazolidine derivatives for treaing urinary incontinence

A compound of Formula I or of Formula II

• 14
• wherein:
• R1 is H, Me, F, Cl, Br, CH2F, CF2H, or CF3;
• R2is NR6R7, where R6 is Me, Et, Pr, or iPr, and R7 is Me, Et or Pr;
• R3 and R5 are each independently H, Me, F, Cl, Br, CH2F, CF2H, or CF3;
• and
• R4 is Me, F, Cl, Br, CH2F, CF2H, or CF3;
• or a pharmacologically acceptable salt thereof.

A compound of Formula I or of Formula II

• 15
• wherein:
• R1 is F, Cl, Br, CH2F, CF2H, or CF3;
• R2is NR6R7, where R6 is Me, Et, Pr, or iPr, and R7 is Me, Et or Pr;
• R3 and R4 are each independently H, Me, F, Cl, Br, CH2F, CF2H, or CF3, and if R4 is Me, F, Cl, Br, CH2F, CF2H, or CF3, then R1 is additionally H or Me;
• and
• R5 is Me, F, Cl, Br, CH2F, CF2H, or CF3,
• or a pharmacologically acceptable salt thereof.

A compound of Formula I or of Formula II

• 16
• wherein:
• R1 is H, Me, F, Cl, Br, CH2F, CF2H, or CF3;
• R2is NR6R7, where R6 is Me, Et, Pr, or iPr, and R7 is Me, Et or Pr;
• R3 and R4 are each independently Me, F, Cl, Br, CH2F, CF2H, or CF3;
• R5 is H, Me, F, Cl, Br, CH2F, CF2H, or CF3,
• or a pharmacologically acceptable salt thereof.

A compound of Formula I or of Formula II

• 17
• wherein:
• R1 is H, Me, F, Cl, Br, CH2F, CF2H, or CF3;
• R2is NR6R7, where R6 is Me, Et, Pr, or iPr, and R7 is Me, Et or Pr;
• R3 is H, Me, F, Cl, Br, CH2F, CF2H, or CF3;
• and
• R4 and R5 are each independently Me, F, Cl, Br, CH2F, CF2H, or CF3;
• or a pharmacologically acceptable salt thereof.

A compound of Formula I or of Formula II

• 18
• wherein:
• R1 is H, Me, F, Cl, Br, CH2F, CF2H, or CF3;
• R2is NR6R7, where R6 is Me, Et, Pr, or iPr, and R7 is Me, Et or Pr;
• R3 and R5 are each independently Me, F, Cl, Br, CH2F, CF2H, or CF3;
• and
• R4 is H, Me, F, Cl, Br, CH2F, CF2H, or CF3, and if R4 is Me, F, Cl, Br, CH2F, CF2H, or CF3, then R1 is additionally H or Me,
• or a pharmacologically acceptable salt thereof.

A compound of Formula I or of Formula II

• 19
• wherein:
• R1 is H, Me, F, Cl, Br, CH2F, CF2H, or CF3;
• R2is NR6R7, where R6 is Me, Et, Pr, or iPr, and R7 is Me, Et or Pr;
• and
• R3, R4, and R5 are each independently Me, F, Cl, Br, CH2F, CF2H, or CF3,
• or a pharmacologically acceptable salt thereof.

A compound of Formula I or of Formula II

• 20
• wherein:
• R1 is H, Me, F, Cl, Br, or CF3;
• R2is NR6R7;
• R3 and R5 are each independently H, F, Cl, Br, or CF3;
• R4 is F, Cl, Br, or CF3;
• and
• R6 and R7 are each independently Me or Et.

A compound selected from the group consisting of:

• (a) 2′-bromo-3′-chloro-5′-dimethylamino-6′-methylphen-1′-yl-2-iminoimidazolidine;
• (b) 3′-bromo-5′-diethylamino-6′-methylphen-1′-yl-2-iminoimidazolidine;
• (c) 3′-bromo-5′-dimethylamino-6′-methylphen-1′-yl-2-iminoimidazolidine;
• (d) 3′-chloro-5′-dimethylamino-6′-methylphen-1′-yl-2-iminoimidazolidine;
• (e) 2′-3′-dibromo-5′-dimethylamino-6′-methylphen-1′-yl-2-iminoimidazolidine;
• (f) 2′-chloro-3′-dimethylaminophen-1′-yl-2-iminoimidazolidine;
• (g) 4′-bromo-2′-chloro-3′-dimethylaminophen-1′-yl-2-iminoimidazolidine;
• (h) 2′-bromo-6′-chloro-5′-dimethylaminophen-1′-yl-2-iminoimidazolidine;
• and
• (i) 5′-bromo-2′-chloro-3′-dimethylaminophen-1′-yl-2-iminoimidazolidine, or a tautomer thereof or a corresponding pharmacologically-compatible salt thereof.

A compound selected from the group consisting of:

• (a) 2′-bromo-3′-chloro-5′-dimethylamino-6′-methylphen-1′-yl-2-iminoimidazolidine;
• (b) 3′-bromo-5′-dimethylamino-6′-methylphen-1′-yl-2-iminoimidazolidine;
• (c) 3′-chloro-5′-dimethylamino-6′-methylphen-1′-yl-2-iminoimidazolidine;
• and
• (d) 2′-3′-dibromo-5′-dimethylamino-6′-methylphen-1′-yl-2-iminoimidazolidine, or a tautomer thereof or a corresponding pharmacologically-compatible salt thereof.